Search
Neovastat
go.drugbank.com/drugs/DB05387InvestigationalNeovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international...
Raseglurant
go.drugbank.com/drugs/DB05070InvestigationalADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for t...
Dirithromycin
go.drugbank.com/drugs/DB00954InvestigationalDirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalThe drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTM5614
go.drugbank.com/drugs/DB16516InvestigationalAn animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
ALT-2074
go.drugbank.com/drugs/DB05631InvestigationalAn organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.
RP01
go.drugbank.com/drugs/DB05751ExperimentalIt is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.
alpha-Hydroxy glycineamide
go.drugbank.com/drugs/DB06568ExperimentalIt also has an effect on viral gp160 envelope protein. [A31692]